Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
In brief
Ackman’s endorsement highlights a growing push for transparent drug pricing that could reward insurers embracing lower‑cost models while squeezing PBMs that rely on opaque rebates and spread pricing.